Concurrent chemotherapy in advanced head and neck carcinoma A prospective randomized trial
DOI:
https://doi.org/10.3329/bjo.v17i2.8847Keywords:
Advanced head and neck cancer, Concurrent chemo-radiation, weekly versus three weekly cisplatin.Abstract
Purpose: The aim of this study is to compare two different concurrent chemoradiotherapy regimes – weekly cisplatin and three weekly cisplatin along with standard external beam radiotherapy in advanced head and neck cancer.
Procedures: 90 untreated patients of advanced squamous cell carcinoma of head and neck were randomized into three arms: Arm A (n=30) patients received inj cisplatin 30mg/m2 weekly along with radiation; Arm B (n=30) patients received inj. cisplatin 100mg/m2 on a three weekly basis with radiation; Arm C (n=30) received only radiation. Radiotherapy was delivered to a dose of 66 Gy to 70 Gy in conventional fractionation in telecobalt machine.
Findings: Complete response rate is significantly higher in arm B compared to that of arm A and arm C. Major toxicitities include neutropenia, anaemia and mucositis. Grade 3 neutropenia, anaemia and mucositis were found in arm A and arm B. No grade 3 toxicity was found in arm C. There was no grade 4 toxicity in any arm.
Conclusion: We conclude that concurrent chemoradiation produce better response compared to that of radiation only. Toxicities were also increased in concurrent regimes. Out of two concurrent regimes, three weekly regimes showed better response with slightly increased but manageable hematological toxicities. Hence, this regime can be considered as standard of care for advanced head and neck cancer.
Key words: Advanced head and neck cancer; Concurrent chemo-radiation; weekly versus three weekly cisplatin.
DOI: http://dx.doi.org/10.3329/bjo.v17i2.8847
BJO 2011; 17(2): 88-95
Downloads
150
133
Downloads
How to Cite
Issue
Section
License
Manuscripts submitted for publication in the Bangladesh Journal of Otorhinolaryngology must not have been previously submitted or published. Accepted papers become the permanent property of the Bangladesh Journal of Otorhinolaryngology. By submitting a manuscript, the authors(s) agree that copyrights for their articles are automatically transferred to Bangladesh Journal of Otorhinolaryngology, if and when the articles are accepted for publication.
The use, in this journal, of registered trade names, trade marks, etc. without special acknowledgement does not imply that such names, as defined by the relevant protection laws, be regarded as unprotected, and, thus, free for general use.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
